---
title: 'The emerging perioperative treatment paradigm for non-small cell lung cancer:
  a narrative review'
date: '2024-02-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38372058/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240219170653&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Perioperative immunotherapy is becoming the dominant treatment
  paradigm for resectable NSCLC, while increasing use of targeted drugs for actionable
  alterations necessitates upfront molecular profiling of early tumors for patient
  ...'
disable_comments: true
---
CONCLUSIONS: Perioperative immunotherapy is becoming the dominant treatment paradigm for resectable NSCLC, while increasing use of targeted drugs for actionable alterations necessitates upfront molecular profiling of early tumors for patient ...